Arthritis News and Research

Latest Arthritis News and Research

Achievement of physical activity goals linked to reduced arthritis pain, increased quality of life

Researchers from The Netherlands report that patients with rheumatoid arthritis (RA) who have higher levels of self-efficacy for physical activity are more likely to achieve their physical activity goals.

25 Aug 2011

Psoriasis drug and heart attack risk association unclear: Study

According to American researchers, although a review of published studies reveals that a new and highly effective class of psoriasis drugs does not appear to raise the risk of heart problems, the studies may not have been big enough to detect rare cases.

24 Aug 2011

Bacteria tweak their genes and proteins to gain strength

Scientists have discovered that bacteria like E. coli and Salmonella have a sneaky way of making minor alterations to their genes to boost their chances for infection.

24 Aug 2011

MSFHR announces recipients of 2010/11 health research scholar and trainee funding competitions

The Michael Smith Foundation for Health Research (MSFHR) is pleased to announce the recipients of its 2010/11 research scholar and trainee funding competitions. Of the more than 300 applicants, MSFHR has funded 95 individuals working in diverse fields of health research.

24 Aug 2011

Roche Canada grants Vasculitis and Scleroderma Fellowship

Roche Canada announced today its support of a Vasculitis and Scleroderma Fellowship through the Division of Rheumatology at the University of British Columbia (UBC). Dr. Ada Man, a recent graduate of the UBC rheumatology residency program, is the recipient of the one-year Fellowship.

23 Aug 2011

Study: More attention needs to be paid for cartilage during RA diagnosis

This could lead to a paradigm shift in the treatment of rheumatoid arthritis: rheumatologists at the Medical University of Vienna have discovered, through a secondary study involving 3,000 female patients, that the condition of the cartilage in inflammatory joint rheumatism needs to be paid more attention than has previously been the case. Until now, the focus lay mainly on investigating the damage to the bone.

23 Aug 2011

New report on the immunomodulators market outlook to 2016

TNF inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease formed the largest share of the market, according to a new report available on companiesandmarkets.com. The top three products: Remicade, Humira and Enbrel accounted for 40.1% of the market in 2010.

23 Aug 2011

Texas Gov. Rick Perry tries experimental stem cell therapy

Texas Gov. Rick Perry last month underwent a procedure where stem cells, made from fat taken from his body, were put into his bloodstream to see if they might find their way to help heal the bones in his back.

22 Aug 2011

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen today announced that it will present data from several Prolia (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.

19 Aug 2011

CEL-SCI receives Chinese patent for Multikine cancer drug

CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.

18 Aug 2011

New gout drug may help severely affected: Study

A new drug for gout could help very sick gout patients who don't get better with usual treatment, according to a new study. The research was designed and funded by the pharmaceutical company Savient, which markets the drug, called Krystexxa (pegloticase).

17 Aug 2011

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

Protalix BioTherapeutics, Inc., announced today that the U.S. Food & Drug Administration (FDA) has accepted for review the resubmission of the taliglucerase alfa New Drug Application (NDA) following the Company's receipt of a Complete Response Letter (CRL) in February 2011.

17 Aug 2011

Study: Vitamin D directly terminates production of MS-causing protein

While for years scientists have noted an association between levels of vitamin D in a person's body and the person's ability to resist or minimize the effects of multiple sclerosis (MS), the mechanism involved has not been established.

17 Aug 2011

FDA clears Inhibikase IkT-001 Phase II trial to treat JCV infection in multiple sclerosis patients

Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).

17 Aug 2011

Inflammation linked with RA increases patients risk of heart disease

Rheumatoid arthritis (RA) sufferers are at an increased risk of dying due to cardiovascular disease. A new five year study published in BioMed Central's open access journal Arthritis Research & Therapy showed that the risk of cardiovascular disease for people with RA is due to disease-related inflammation as well as the risk factors which affect the general population.

16 Aug 2011

New insights into causes of rheumatoid arthritis

Scientists at Mount Sinai Hospital, in collaboration with researchers at the University of Toronto, University Health Network and McGill University have obtained significant new insights into the causes of rheumatoid arthritis (RA) and other autoimmune disorders including type 1 diabetes, lupus and Graves disease.

16 Aug 2011

Advanced MRI techniques can identify early OA

Researchers from NYU Langone Medical Center's Departments of Orthopaedic Surgery and Radiology found that advanced MRI techniques can be used to detect subtle changes in joint cartilage microstructure - and provide physicians a diagnostic tool for finding key markers of early osteoarthritis.

16 Aug 2011

Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. has announced that the first patients have been enrolled and randomized to receive RGN-259 or placebo in its 72-patient, Phase 2 clinical trial in patients with dry eye syndrome.

16 Aug 2011

Toclizumab for juvenile rheumatoid arthritis

The arthritis drug Toclizumab could be a boon for hundreds of children suffering from severe arthritis. It has been re-launched in children after being already licensed for the treatment of adults. At least two thirds of children taking tocizilumab have been able to return to a normal life, after many were bedridden or forced into wheelchairs by the disease, the clinical studies reveal.

16 Aug 2011

Medgenics second quarter net loss increases to $2.32 million

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three and six months ended June 30, 2011.

12 Aug 2011